Dr. Suleman (Suli) Verjee, Ph.D., President and CEO of Versante International, LLC., has over 30 years of drug development experience with both pharmaceutical and biotechnology companies. Prior to founding Versante, a full service biometrics-focused contract research organization in 2002, Dr. Verjee held senior management positions at several leading multinational companies. These include Abbott Laboratories, Ethicon Inc. (a division of Johnson and Johnson), Parke-Davis/Warner Lambert, Bristol-Myers Company, Lorex Pharmaceuticals, Berlex Laboratories (now part of Bayer) and Dendreon Corporation. Dr. Verjee has an intimate knowledge of all phases of drug development and has a track record of successful New Drug (NDA) and Biological License (BLA) Applications. The drug development programs he has been associated with and made significant contributions to include those for Ambien, Betaseron, Buspar, Depakene, Enkaid, Fludara, Kerlone and Provenge. His numerous interactions with regulatory agencies include Special Protocol Assessments (SPA), Electronic Submissions and Advisory Committee Meetings. He has been a member of several data safety monitoring and scientific advisory boards. Dr. Verjee’s experience spans hundreds of clinical studies. Dr. Verjee received his doctoral degree in Statistics from the University of Chicago where he studied under Professors Shelby Haberman and Paul Meier. His academic teaching experience includes teaching undergraduate statistics courses at the University of Chicago and the University of Illinois as well as graduate level courses in statistics at IMPA (Instituto de Matematica, Pura e Aplicada in Rio de Janeiro), Universidade de Campinas (San Paulo) and the Universidade Federal de Minas Gerais (Belo Horizonte).